Penumbra, Inc. PEN

Penumbra, Inc. reported its second quarter 2026 financial results. Quarterly financial results release supplies performance data that can shift near-term investor views and valuation.

Penumbra launches THUNDERBOLT product; analysis questions if PEN stock is undervalued or fairly priced post-debut. THUNDERBOLT product launch represents major strategic move likely to shift Penumbra's trajectory and investor sentiment.

Penumbra gains FDA clearance for THUNDERBOLT device following strong results in stroke study. FDA clearance for THUNDERBOLT adds approved stroke device and supports revenue growth trajectory.

THUNDER Study confirms Penumbra's THUNDERBOLT device as safe and effective for stroke care. Positive THUNDER study results validate THUNDERBOLT and strengthen Penumbra's position in stroke treatment devices.

Penumbra enrolls first patient in FORWARD study assessing mechanical thrombectomy and computer assisted vacuum thrombectomy for distal acute ischemic stroke. First-patient enrollment in FORWARD study marks incremental progress in Penumbra's core stroke-treatment pipeline.

Penumbra receives CE mark approval for THUNDERBOLT, positioning the stock for potential gains. CE approval for THUNDERBOLT opens European market access and supports revenue growth.

Penumbra wins CE mark for Thunderbolt clot removal tech. CE mark enables European commercialization of new clot removal device.

Penumbra gains Thunderbolt approval to accelerate neuro thrombectomy innovation and product development. Thunderbolt approval drives major advances in core neurovascular devices and competitive positioning.

Penumbra gains CE Mark approval for THUNDERBOLT, expanding its CAVT stroke treatment to Europe. CE Mark for THUNDERBOLT opens European market access for core stroke therapy, driving revenue growth.

Boston Scientific targets neurovascular growth via Penumbra Thunderbolt clearance. Thunderbolt clearance opens major neurovascular revenue and partnership opportunities for Penumbra with Boston Scientific.

FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke treatment. FDA clearance of new core-product platform enables commercial launch and expands addressable stroke market.

Penumbra gains FDA approval for clot removal technology, delivering a direct benefit to Boston Scientific. FDA clearance opens commercial use of Penumbra's core technology and lifts growth prospects.

RBC says Penumbra's Thunderbolt device offers revenue upside not reflected in estimates. Analyst note on Thunderbolt device revenue potential indicates moderately noticeable positive effect on Penumbra financial performance and investor sentiment.

Penumbra receives FDA clearance for THUNDERBOLT, introducing computer-assisted vacuum thrombectomy technology for stroke treatment. FDA clearance for THUNDERBOLT adds advanced core technology that strengthens Penumbra's market position in stroke devices.

Penumbra (PEN) revenue growth and margin expansion are supported by key operational and market factors that bolster financial performance. Support for sustained revenue growth and margin expansion signals moderately improved financial trajectory and competitive positioning.

Penumbra, Inc. reported first quarter 2026 financial results. Quarterly earnings reports significantly impact stock performance and investor sentiment through revenue, EPS, and guidance updates.

Penumbra (PEN) missed Q1 earnings estimates. Missing Q1 earnings highlights weaker financial performance, moderately affecting investor sentiment and near-term stock trajectory.

Boston Scientific (BSX) acquires Penumbra (PEN), triggering valuation review of BSX alongside recent shareholder returns. Penumbra's acquisition by Boston Scientific fundamentally transforms its operational independence, market position, and long-term prospects.

STORM-PE data shows computer-assisted vacuum thrombectomy with anticoagulation delivers significantly better 90-day functional outcomes than anticoagulation alone for pulmonary embolism patients. Positive STORM-PE trial results validate Penumbra's thrombectomy technology superiority, poised to enhance adoption, revenue growth, and stock performance.

Boston Scientific's acquisition of Penumbra, Inc. (PEN) has triggered a review of the deal's valuation amid concerns over its fairness. Acquisition by Boston Scientific fundamentally redefines Penumbra's competitive position and long-term prospects.

E2 raised $80 million to commercialize its thrombectomy platform. E2's $80M raise enables aggressive marketing of a competing thrombectomy platform in Penumbra's core market.

Penumbra (NYSE:PEN) reported the strongest Q4 results in the Medical Devices & Supplies group across Cardiology, Neurology, and Vascular sectors. Strongest Q4 results in core medical device sectors indicate significant positive impact on financial performance and market trajectory.

Boston Scientific's sharp stock dip creates a major investment opportunity for Penumbra, Inc. (PEN). Competitor Boston Scientific's stock plunge offers Penumbra moderately noticeable competitive and market sentiment advantages.

Boston Scientific's recent acquisition of Penumbra prompts valuation reassessment amid BSX share price weakness. Acquisition by Boston Scientific fundamentally redefines Penumbra's independence, operations, and long-term market prospects.

Penumbra (PEN) stock rose after Q4 earnings and revenue beat estimates, with margins improving. Q4 earnings and revenue beat with rising margins indicates strong financial performance driving stock gains and positive investor sentiment.

Boston Scientific faces AXIOS stent recall amid shifts in $11 billion Penumbra, Inc. deal. $11 billion deal shift redefines Penumbra's competitive position and long-term prospects.

Penumbra (PEN) Q4 earnings results compared to analyst estimates, with analysis of key metrics. Q4 earnings comparison to estimates significantly influences financial outlook and investor sentiment.

Penumbra (PEN) beat Q4 earnings and revenue estimates. Beating Q4 earnings and revenue estimates boosts investor sentiment and signals strong financial performance.

Penumbra (NYSE:PEN) reports bullish Q4 CY2025 results. Bullish Q4 CY2025 earnings signal strong financial health and positive momentum for future performance.

Penumbra Inc. (PEN) reported Q4 net income of $16.5 million, or 41 cents per share, versus a prior-year loss. Revenue climbed 24% to $269.4 million, topping estimates of $263.4 million. Strong Q4 revenue growth and profitability beat estimates, signaling positive momentum for future performance and investor confidence.